跳转至内容
Merck
CN

SML3671

Brivanib

≥98% (HPLC)

别名:

BMS-540215, (2R)-1-[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol, (2R)-1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol, (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, BMS 540215, BMS 582664 active drug, BMS-582664 active drug, BMS540215, BMS582664 active drug

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

经验公式(希尔记法):
C19H19FN4O3
化学文摘社编号:
分子量:
370.38
UNSPSC Code:
12352200
NACRES:
NA.25
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Segment

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

Fc1c2c([nH]c(c2)C)ccc1Oc3ncn[n]4c3c(c(c4)OC[C@H](O)C)C

InChI

1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1

InChI key

WCWUXEGQKLTGDX-LLVKDONJSA-N

Biochem/physiol Actions

Brivanib (BMS-540215) is an orally active, ATP-competitive FGF & VEGF receptor tyrosine kinase inhibitor (VEGFR-1/2/3 IC50 = 380/25/10 nM; FGFR-1/2/3 IC50 = 148/125/68 nM). Brivanib inhibits VEGF-stimulated and basic FGF-stimulated proliferation in endothelial cultures (IC50 = 40 & 276 nM, respectively) and displays antitumor efficacy in vivo (30-90 mg/kg via daily p.o. in mice with H3396 xenografts).
Orally active, ATP-competitive FGF & VEGF receptor tyrosine kinase inhibitor with antitumor efficacy in vivo.


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库